World Journal of Dentistry

Register      Login

VOLUME 12 , ISSUE 1 ( January-February, 2021 ) > List of Articles


Immunohistochemical Analysis of ErbB2 in Odontogenic Lesions: A Pilot Study

Surendra Lakshminarayana, Roopa S Rao, Samudrala V Sowmya, Dominic Augustine, Shankargouda Patil, Vanishri C Haragannavar

Keywords : Ameloblastoma, Dentigerous cysts, ErbB2/neu, Immunohistochemistry, Odontogenic keratocyst

Citation Information : Lakshminarayana S, Rao RS, Sowmya SV, Augustine D, Patil S, Haragannavar VC. Immunohistochemical Analysis of ErbB2 in Odontogenic Lesions: A Pilot Study. World J Dent 2021; 12 (1):70-73.

DOI: 10.5005/jp-journals-10015-1796

License: CC BY-NC 4.0

Published Online: 00-02-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Aim and objective: ErbB2 also referred to as CD340, HER2/neu belongs to the human epidermal growth factor receptor (EGFR) family. It is a cell surface receptor kinase involved in the regulation of important events like cell proliferation and differentiation. Phosphorylation of ErbB2 by their ligands causes activation of downstream signaling pathways like phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-Akt pathways. To evaluate the role of ErbB2 in odontogenic keratocysts (OKCs), dentigerous cyst (DC), and ameloblastoma by correlating the expression levels of ErbB2 with the biological behavior of the disease. Materials and methods: The present study comprises 10 histopathologically diagnosed FFPE samples, of OKC, DC, and ameloblastoma among odontogenic lesions. These cases were subjected to immunohistochemical staining with ErbB2 antibody. ASCO/CAP scoring criteria 2013 was employed for interpretation. Membranous reactivity was considered positive. Mann–Whitney U test was used for statistical analysis. Results: The ErbB2 expression levels in nine cases of OKC tissue showed significantly high expression, followed by eight cases of ameloblastoma, and five cases of a DC. All these odontogenic lesions showed positive for cell membrane staining. Conclusion: In the present study, HER2 is highly expressed in the majority of cases of OKC and ameloblastoma. However, further studies with a larger sample size have to be carried out along with other members of the ErbB2 family for definitive inference. Clinical significance: Increased expression of ErbB2 indicates neoplastic transformation.

PDF Share
  1. Kanth KS, Kumar TD, Kumar AR. Immunohistochemical analysis of dentigerous cyst and ameloblastoma using cytokeratin 19 & amp; 14, p53, p63 and ki-67. SRM J Res Dent Sci 2012;3(4):236. DOI: 10.4103/0976-433X.114967.
  2. Shergill AK, Singh P, Charlotte M. Dentigerous cyst associated with an erupted tooth – an unusual presentation. Int J Sci c Study 2014;2:100–102.
  3. Naclério-homem MG. Surgical management of dentigerous cyst and keratocystic odontogenic tumor in children: a conservative approach and 7-year follow-up. J Appl Oral Sci 2012;20(2):282–285. DOI: 10.1590/S1678-77572012000200025.
  4. Shetty A, Nagaraj T, Irugu K, et al. Keratocystic odontogenic tumour - a case report and review of literature. Int J Med Dent Case Rep 2016;2:1–4.
  5. Asareh F, Hashemi A, Haghighizadeh MH. International journal of current research in the immunohistochemichal expression of HER2/neu in odontogenic keratocyst ( OKC) and dental follicle. Int J Curr Res Chem Pharma Sci 2016;3:34–39.
  6. Wood NK, Differential diagnosis of oral and maxillofacial lesions. 1997.
  7. Oikawa M, Miki Y, Shimizu Y, et al. Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas. J Oral Pathol Med 2013;42(5):424–434. DOI: 10.1111/jop.12024.
  8. Masthan KM, Anitha N, Krupaa J, et al. Ameloblastoma. J Pharm Bioallied Sci 2015;7(Suppl 1):S167–170. DOI: 10.4103/0975-7406.155890.
  9. Schroeder RL, Stevens CL, Sridhar J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/neu in the treatment of aggressive breast cancer. Molecules 2014;2(9):15196–15212. DOI: 10.3390/molecules190915196.
  10. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:1–9. DOI: 10.1155/2014/852748.
  11. Le XF, Lammayot A, Gold D, et al. Genes affecting the cell cycle, growth, maintenance drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005;280(3):2092–2104. DOI: 10.1074/jbc.M403080200.
  12. Lakshminarayana S, Augustine D, Rao R, et al. Molecular pathways of oral cancer that predict prognosis and survival: a systematic review. J Carcinog 2018;17(1):7. DOI: 10.4103/jcar.JCar_17_18.
  13. Kumar AbbasA. Robbins and Cotran Pathologic basis of disease. 9th ed., Elsevier; 2015.
  14. Sassen A, Rochon J, Wild P, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008;10(1):1–13. DOI: 10.1186/bcr1843.
  15. Hughes DPM, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of HER-4 in primary osteosarcoma. Cancer Res 2004;64(6):2047–2053. DOI: 10.1158/0008-5472.CAN-03-3096.
  16. Asaare F, Leila Haghighizadeh MHH. International journal of current research in amloblastoma and dental follicle. Int J Curr Res Chem Pharma Sci 2015;2:86–90.
  17. Monsef Esfahani F, Irani S. HER2/neu in odontogenic cysts. URMIA Med J 2012;23:513–520.
  18. Abdel-Aziz A, Amin MM. EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence. Diagn Pathol 2012;7(1):14. DOI: 10.1186/1746-1596-7-14.
  19. Esfehani F, Irani S. HER2/Neu expression in odontogenic cycsts. Urmia Med J 1991;23:513–523.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.